Khawla Abusamra, MD
Neurology · Hutchinson, KSNPI 1972969657
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,442, 4.0 times the $616 reported in 2023.
Across 316 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$668
- Novartis$416
- EMD Serono, Inc.$396
- Harmony Biosciences LLC$395
- UCB, Inc.$351
- Neurocrine Biosciences, Inc.$342
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,11597%
- Education$1823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 46 | $668 |
| Novartis | 30 | $416 |
| EMD Serono, Inc. | 30 | $396 |
| Harmony Biosciences LLC | 12 | $395 |
| UCB, Inc. | 14 | $351 |
| Neurocrine Biosciences, Inc. | 17 | $342 |
| Bristol Myers Squibb | 18 | $300 |
| AbbVie | 44 | $286 |
| Teva Pharmaceuticals USA, Inc. | 17 | $268 |
| Genentech USA, Inc. | 10 | $214 |
| Kyowa Kirin, Inc. | 8 | $162 |
| Lilly USA, LLC | 9 | $153 |
| Eisai Inc. | 6 | $149 |
| Lundbeck LLC | 3 | $126 |
| Sumitomo Pharma America, Inc. | 5 | $106 |
| Amgen | 5 | $103 |
| Biogen | 4 | $86 |
| ANI Pharmaceuticals, Inc. | 4 | $81 |
| SK Life Science, Inc. | 4 | $71 |
| Acadia Pharmaceuticals Inc | 3 | $69 |
| TG Therapeutics, Inc. | 3 | $67 |
| Genentech, Inc. | 1 | $67 |
| AstraZeneca | 2 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Hospira, Inc. | 5 | $37 |
| GE HealthCare | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Argenx US, Inc. | 1 | $33 |
| Grifols USA, LLC | 1 | $27 |
| Amylyx Pharmaceuticals, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$5,297 in reported general payments places this provider in the 75th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $171,265 |
| Nurtec OdtRimegepant Sulfate | 52 | $85,073 |
| QuliptaAtogepant | 19 | $26,691 |
| UbrelvyUbrogepant | 13 | $19,411 |
| ZavzpretZavegepant Hcl | 15 | $16,443 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $10,734 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $10,153 |
| Memantine Hcl | 121 | $2,952 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 161 | $2,767 |
| Levetiracetam | 52 | $1,766 |
| Donepezil Hcl | 248 | $1,523 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 25 | $1,504 |
| Gabapentin | 107 | $619 |
| Nortriptyline Hcl | 57 | $559 |
| Ropinirole Hcl | 37 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $342 | $171,26521 claims |
| PfizerNurtec Odt, Zavzpret | $668 | $101,51767 claims |
| AbbVieQulipta, Ubrelvy | $286 | $46,10232 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $23 | $38411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 131 neurology providers in Kansas.
Other neurology in Hutchinson
- Rizwan HassanHutchinson$4K
- William MalloneeHutchinson$2K
- Dustin HarkerHutchinson$1K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.